Pennsylvania 2025-2026 Regular Session Status: In Committee Bipartisan · 3 D · 3 R cosponsors

SB 826 — An Act amending the act of October 24, 2018 (P.L.719, No.112), known as the Patient Test Result Information Act, further providing for definitions; providing for Lyme disease testing disclosure; and imposing duties on health care practitioners.

Last action — Referred to Health & Human Services

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced June 03, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Prognosis

Advancing 42% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 6 sponsors

    1 primary, 5 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (3 D · 3 R) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Bill Text

How this bill changes current law

2 changes Share ↗

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

The bill adds definitions and requirements regarding Lyme disease test result disclosures for healthcare practitioners and clinical laboratories in Pennsylvania.

  • Section 2

    "Clinical laboratory." As defined in section 2 of the act of September 26, 1951 (P.L.1539, No.389), known as The Clinical Laboratory Act.

    Adds a definition for 'Clinical laboratory' to clarify what it means in the context of the act.

  • Section 3.1. Lyme disease testing disclosure. (a) Notice to health care practitioner.--When a clinical laboratory is reporting a Lyme disease test result ordered by a health care practitioner, the clinical laboratory shall provide notice to the health care practitioner, which shall include, at minimum, the following disclosure: Patients undergoing a Lyme disease test should be aware that Lyme disease tests vary and may produce results that are not accurate. This means a patient may not be able to rely on a positive or negative test. If you continue to experience symptoms, you should contact your health care provider and inquire about the appropriateness of retesting and the applicability for pursuing additional or alternative treatment options. (b) Notice to patient required.--A health care practitioner receiving a notice under subsection (a) shall provide the notice to the patient who is the subject of the Lyme disease test result at the time the health care practitioner provides the patient the test results from the clinical laboratory. (c) Existing medical professional duty and obligation.--Nothing in this act shall be construed as relieving a health care practitioner from complying with an existing professional obligation to inform a patient of test results.

    Establishes a new section that requires clinical laboratories to notify healthcare practitioners of Lyme disease test result limitations and compels healthcare practitioners to inform patients accordingly.

Action History

  1. Referred to Health & Human Services

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 5 co-sponsors · 247 not signed on

Sponsors (1)

Co-sponsors (5)

Not signed on (247)

247 members have not signed on to this bill.

Show all 247 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors SB 826?
SB 826 is sponsored by Marty Flynn (Democratic), Daniel Laughlin (Republican), Jay Costa (Democratic), Camera Bartolotta (Republican), Lisa M. Boscola (Democratic), and Greg Rothman (Republican).
What is the current status of SB 826?
This bill is in committee in the Senate. Introduced June 03, 2025. It must pass committee before a floor vote.
Where can I track SB 826?
Track SB 826 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 826

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 826

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →